SYNLOGIC, INC. Restricted Cash and Cash Equivalents, Noncurrent
SYNLOGIC, INC. (SYBX) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2017-06-30, per its 10-Q filed 2017-08-04.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2017-08-04
- 2017-06-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2017-03-31: Restricted Cash and Cash Equivalents, Noncurrent $2.43M.
- 2016-12-31: Restricted Cash and Cash Equivalents, Noncurrent $2.43M.
- 2016-09-30: Restricted Cash and Cash Equivalents, Noncurrent $2.43M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2017-06-30 | $0.00 10-Q · filed 2017-08-04 |
| 2017-03-31 | $2.43M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $2.43M 10-Q · filed 2017-08-04 |
| 2016-09-30 | $2.43M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $2.43M 10-Q · filed 2016-08-15 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |